Back to Search
Start Over
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: Results of the randomized AZABACHE Spanish trial
- Source :
- Zaguán. Repositorio Digital de la Universidad de Zaragoza, instname, Digital.CSIC. Repositorio Institucional del CSIC, HAEMATOLOGICA, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid, Consejería de Sanidad de la Comunidad de Madrid, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
- Publication Year :
- 2015
-
Abstract
- This is an open-access paper.-- This trial was registered in the ClinicalTrials.gov database with code NCT01087008.<br />Spanish Myeloma Group (GEM/PETHEMA): et al.<br />This study analyzed the anti-myeloma effect of zoledronic acid monotherapy by investigating patients at the time of asymptomatic biochemical relapse. One hundred patients were randomized to receive either zoledronic acid (4 mg iv/4 weeks, 12 doses) (n=51) or not (n=49). Experimental and control groups were well balanced for disease and prognostic features. Zoledronic acid did not show an antitumor effect according to changes in M-component. However, there were fewer symptomatic progressions in the experimental group than in the control group (34 versus 41, respectively; P=0.05) resulting in a median time to symptoms of 16 versus 10 months (P=0.161). The median time to next therapy was also slightly longer for the treated group than the untreated, control group (13.4 versus 10.1 months), although the difference was not statistically significant (P=0.360). The pattern of relapses was different for treated versus control patients: progressive bone disease (8 versus 20), anemia (24 versus 18), renal dysfunction (1 versus 2), and plasmacytomas (1 versus 1, respectively). This concurred with fewer skeletal-related events in the treated group than in the control group (2 versus 14), with a projected 4-year event proportion of 6% versus 40% (P<br />This work was supported by an unrestricted grant from Novartis Farmaceutica S.A., Barcelona, Spain and sponsored by GEM/PETHEMA. Part of the work was also done thanks to grants PS09/01450 and PI12/02311 from the Spanish “Instituto de Salud Carlos III (ISCIII)” and Fondo Europeo de Desarrollo Regional (FEDER), the Spanish Ministry of Economy and Competitiveness and the European Regional Development Fund (ERDF) “Una manera de hacer Europa” (Innocampus; CEI-2010-1-0010), the grant RD12/0036/0069 from “Red Temática de Investigación Cooperativa en Cáncer (RTICC), and grant GCB-120981SAN from the “Asociación Española Contra el Cáncer (AECC)”.
- Subjects :
- Adult
medicine.medical_specialty
Bone disease
Anemia
InformationSystems_INFORMATIONSTORAGEANDRETRIEVAL
Asymptomatic
Gastroenterology
Zoledronic Acid
Disease-Free Survival
Internal medicine
medicine
Humans
Survival rate
Multiple myeloma
Aged
Treated group
Diphosphonates
business.industry
Mieloma múltiple
Imidazoles
Articles
Hematology
Middle Aged
medicine.disease
Surgery
Survival Rate
Zoledronic acid
Biochemical relapse
medicine.symptom
Bone Diseases
business
Multiple Myeloma
medicine.drug
Subjects
Details
- ISSN :
- 03906078
- Database :
- OpenAIRE
- Journal :
- Zaguán. Repositorio Digital de la Universidad de Zaragoza, instname, Digital.CSIC. Repositorio Institucional del CSIC, HAEMATOLOGICA, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid, Consejería de Sanidad de la Comunidad de Madrid, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
- Accession number :
- edsair.doi.dedup.....d3716ad035a9ca628815ef344dd1a5be